Synmosa Biopharma: The Board of Directors of Synmosa decides to increase the share capital by recapitalization of results

Close
Provided by: SYNMOSA BIOPHARMA CORPORATION |
|||||
SEQ_NO |
4 |
announcement date |
2022/03/29 |
Announcement time |
15:29:32 |
Topic |
The Board of Synmosa resolves to increase capital stock by earnings recapitalization |
||||
Date of events |
2022/03/29 |
What item it responds to |
paragraph 11 |
||
Declaration |
1.Date of the board of directors resolution:2022/03/29 2.Source of capital increase funds:profit for fiscal 2021 3.Whether to adopt shelf registration (Yes, please state issuance period/No):No 4.Total monetary value of the issuance and number of shares issued (shares issued not including those distributed to employees if consisting in capital increase from earnings or capital surplus): 30,016,520 shares,AMOUT NTD 300,165,200 5.If adopting shelf registration, monetary value and number of shares to be issued this time:Not applicable 6.The remaining monetary value and shares after this issuance when adopting shelf registration:Not applicable 7.Par value per share:NTD $10 8.Issue price:Not applicable 9.Number of shares subscribed for by or allocated to employees: Not applicable 10.Number of shares publicly sold:Not applicable 11.Ratio of shares subscribed by or allotted as stock dividends to existing shareholders: 100 share distributed gratis per 1,000 share 12.Handling method for fractional shares and shares unsubscripted for by the deadline: If the stock dividends include any fractional shares which are less than one full share, the shareholders of two or more may arrange for pooling together of their fractional shares to form one full share and register the same under the name of one of the shareholders within 5 days after the ex-rights date. For the fractional shares which cannot be pooled within the specified period, such remainder will be subscribed by designated individuals arranged by the Chairman . 13.Rights and obligations of these newly issued shares: The same as the issued and existing shares. 14.Utilization of the funds from the capital increase: Not applicable 15.Any other matters that need to be specified: (1)If the outstanding shares changed result in the distributing ratio of stock dividends changed, the final ratio will be determined fully by the Board authorized by Shareholders'Meeting. (2)If the plan of increasing capital stock is changed by the authorities, it is determined fully to chang by the Board as authorized by the Shareholders' Meeting. (3)The ex-rights date will be determined fully by the Board as authorized by the Shareholders' Meeting after the capital stock increase is approved by the authorities. |
Warning
Synmosa Biopharma Company published this content on March 29, 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unmodified, on March 29, 2022 07:43:02 UTC.
Public now 2022
|
|
|
|
|
||||
|
||||
Trends in Technical Analysis SYNMOSA BIOPHARMA CORPORATION
Short term | Middle term | Long term | |
Tendencies | Neutral | Bullish | Bullish |
Evolution of the income statement